- Works count
- 863
- Citation count
- 62,211
- H-index
- 95
- i10-index
- 381
Research interests
Publications
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30937-9
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31046-2
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31827-5
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(10)61121-x
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
The Lancet Oncology · 2008 · https://doi.org/10.1016/s1470-2045(08)70285-7
Current projects
No projects listed.